Abstract
We investigated the efficacy of a potent new antipseudomonal β-lactam agent, ceftazidime, in a model of right-sided Pseudomonas endocarditis in 72 rabbits. Animals received either: no therapy (controls), amikacin (15 mg/kg/day), ceftazidime (100 mg/kg/day) or amikacin + ceftazidime. Amikacin + ceftazidime was significantly more effective than single-drug regimens in terms of reduction of mortality (p<0.01), prevention of pulmonary infarction (p<0.05), reduction of mean vegetation titers of Pseudomonas aeruginosa (p<0.05 - p<0.0005), sterilization of vegetations (p<0.0005) and reduction in prevalence of bacteriologic relapse after therapy (p<0.005). There was no development of resistance in vivo to either amikacin or ceftazidime.
Original language | English (US) |
---|---|
Pages (from-to) | 351-361 |
Number of pages | 11 |
Journal | CHEMOTHERAPY |
Volume | 31 |
Issue number | 5 |
DOIs | |
State | Published - Jan 1 1985 |
Externally published | Yes |
ASJC Scopus subject areas
- Oncology
- Pharmacology
- Drug Discovery
- Pharmacology (medical)
- Infectious Diseases